Document:

EXHIBIT 4.1

                                                                  WARRANT NO. 59

THIS WARRANT AND THE UNDERLYING SHARES OF COMMON STOCK HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY
OTHER SECURITIES LAWS, HAVE BEEN TAKEN FOR INVESTMENT, AND MAY NOT BE SOLD OR
TRANSFERRED OR OFFERED FOR SALE OR TRANSFER UNLESS A REGISTRATION STATEMENT
UNDER THE SECURITIES ACT AND OTHER APPLICABLE SECURITIES LAWS WITH RESPECT TO
SUCH SECURITIES IS THEN IN EFFECT, OR IN THE OPINION OF COUNSEL TO THE ISSUER OF
THESE SECURITIES, SUCH REGISTRATION UNDER THE SECURITIES ACT AND OTHER
APPLICABLE SECURITIES LAWS IS NOT REQUIRED.

                             Date: JANUARY 20, 2006

                                     FORM OF
                      WARRANT FOR THE PURCHASE OF SHARES OF

                    COMMON STOCK OF CYGENE LABORATORIES, INC.

         THIS IS TO CERTIFY that, for value received, PETER JON LAURENCE, his
successors and assigns (collectively, the "Holder"), is entitled to purchase,
subject to the terms and conditions hereinafter set forth, 650,000 shares of
CyGene Laboratories, Inc.'s, a Delaware corporation (the "Company") common
stock, $0.001 par value per share ("Common Stock"), and to receive certificates
for the Common Stock so purchased. The exercise price of the warrant is $0.50,
subject to adjustment as provided below.

         1. EXERCISE PERIOD AND VESTING. This Warrant shall fully vest and
become exercisable by the Holder upon the earlier of (i) the effective date of
the Company's registration statement with the Securities and Exchange Commission
covering the shares of Common Stock underlying this Warrant or (ii) one year
from the issuance of this Warrant, with such exercise period ending at 5:00
p.m., New York, New York time, FIVE YEARS thereafter (the "Exercise Period").
This Warrant will terminate automatically and immediately upon the expiration of
the Exercise Period.

         2. EXERCISE OF WARRANT; CASHLESS EXERCISE. This Warrant may be
exercised, in whole or in part, at any time and from time to time during the
Exercise Period. Such exercise shall be accomplished by tender to the Company of
the purchase price set forth above as the warrant price (the "Warrant Price"),
either (a) in cash, by wire transfer or by certified check or bank cashier's
check, payable to the order of the Company, or (b) by surrendering such number
of shares of Common Stock received upon exercise of this Warrant with a current
market price equal to the Warrant Price (a "Cashless Exercise"), together with
presentation and surrender to the Company of this Warrant with an executed
subscription in substantially the form attached hereto as Exhibit A (the
"Subscription"). Upon receipt of the foregoing, the Company will deliver to the
Holder, as promptly as possible, a certificate or certificates representing the

                                       1
<PAGE>
                                                                  WARRANT NO. 59

shares of Common Stock so purchased, registered in the name of the Holder or its
transferee (as permitted under Section 3 below). With respect to any exercise of
this Warrant, the Holder will for all purposes be deemed to have become the
holder of record of the number of shares of Common Stock purchased hereunder on
the date a properly executed Subscription and payment of the Warrant Price is
received by the Company (the "Exercise Date"), irrespective of the date of
delivery of the certificate evidencing such shares, except that, if the date of
such receipt is a date on which the stock transfer books of the Company are
closed, such person will be deemed to have become the holder of such shares at
the close of business on the next succeeding date on which the stock transfer
books are open. Fractional shares of Common Stock will not be issued upon the
exercise of this Warrant. In lieu of any fractional shares that would have been
issued but for the immediately preceding sentence, the Holder will be entitled
to receive cash equal to the Current Market Price of such fraction of a share of
Common Stock on the trading day immediately preceding the Exercise Date. In the
event this Warrant is exercised in part, the Company shall issue a new Warrant
to the Holder covering the aggregate number of shares of Common Stock as to
which this Warrant remains exercisable for.

         If the Holder elects to conduct a Cashless Exercise, the Company shall
cause to be delivered to the Holder a certificate or certificates representing
the number of shares of Common Stock computed using the following formula:

         X = Y (A-B)
               -----
                 A

         Where:
                    X    =   the number of shares of Common Stock to be issued
                             to Holder;

                    Y    =   the portion of the Warrant (in number of shares
                             of Common Stock) being exercised by Holder (at the
                             date of such calculation);

                    A    =   the fair market value of one share of Common
                             Stock on the Exercise Date (as calculated below);
                             and

                    B    =   Warrant Price (as adjusted to the date of such
                             calculation).

         For purposes of the foregoing calculation, "fair market value of one
share of Common Stock on the Exercise Date" shall mean: (i) if the principal
trading market for such securities is a national securities exchange, the Nasdaq
National Market System, Nasdaq Small Cap Market or the Over-the-Counter Bulletin
Board ("OTCBB") (or a similar system then in use), the average last reported
sales price on the principal market for the 10 trading days immediately prior to
such Exercise Date; or (ii) if (i) is not applicable, and if bid and ask prices
for shares of Common Stock are reported by the principal trading market or the
National Quotation Bureau, the average of the high bid and low ask prices so
reported for the 10 trading days immediately prior to such Exercise Date.
Notwithstanding the foregoing, if there is no last reported sales price or bid
and ask prices, as the case may be, for the period in question, then the fair

                                       2
<PAGE>
                                                                  WARRANT NO. 59

market value of one share of Common Stock on the Exercise Date shall be
determined as of the latest 10 day period prior to such day for which such last
reported sales price or bid and ask prices, as the case may be, are available,
unless such securities have not been traded on an exchange or in the
over-the-counter market for 30 or more days immediately prior to the day in
question, in which case the Current Market Price shall be determined in good
faith by, and reflected in a formal resolution of, the board of directors of the
Company. The Company acknowledges and agrees that this Warrant was issued on the
Issuance Date.

         3. TRANSFERABILITY AND EXCHANGE.

                  (a) This Warrant, and the Common Stock issuable upon the
exercise hereof, may not be sold, transferred, pledged or hypothecated unless
the Company shall have been provided with an opinion of the Company's counsel
that such transfer is not in violation of the Securities Act of 1933, and any
applicable state securities laws. Subject to the satisfaction of the aforesaid
condition, this Warrant and the underlying shares of Common Stock shall be
transferable from time to time by the Holder upon written notice to the Company.
If this Warrant is transferred, in whole or in part, the Company shall, upon
surrender of this Warrant to the Company, deliver to each transferee a Warrant
evidencing the rights of such transferee to purchase the number of shares of
Common Stock that such transferee is entitled to purchase pursuant to such
transfer. The Company may place a legend similar to the legend at the top of
this Warrant on any replacement Warrant and on each certificate representing
shares issuable upon exercise of this Warrant or any replacement Warrants. Only
a registered Holder may enforce the provisions of this Warrant against the
Company. A transferee of the original registered Holder becomes a registered
Holder only upon delivery to the Company of the original Warrant and an original
Assignment, substantially in the form set forth in Exhibit B attached hereto.

                  (b) This Warrant is exchangeable upon its surrender by the
Holder to the Company for new Warrants of like tenor and date representing in
the aggregate the right to purchase the number of shares purchasable hereunder,
each of such new Warrants to represent the right to purchase such number of
shares as may be designated by the Holder at the time of such surrender.

         4. ADJUSTMENTS TO WARRANT PRICE AND NUMBER OF SHARES SUBJECT TO
WARRANT. The Warrant Price and the number of shares of Common Stock purchasable
upon the exercise of this Warrant are subject to adjustment from time to time
upon the occurrence of any of the events specified in this Section 4. For the
purpose of this Section 4, "Common Stock" means shares now or hereafter
authorized of any class of common stock of the Company and any other stock of
the Company, however designated, that has the right to participate in any
distribution of the assets or earnings of the Company without limit as to per
share amount (excluding, and subject to any prior rights of, any class or series
of preferred stock).

                  (a) In case the Company shall (i) pay a dividend or make a
distribution in shares of Common Stock to holders of shares of Common Stock,
(ii) split, subdivide its outstanding shares of Common Stock into a greater
number of shares, (iii) combine its outstanding shares of Common Stock into a
smaller number of shares, or (iv) issue by reclassification of its shares of
Common Stock other securities of the Company, then the Warrant Price in effect

                                       3
<PAGE>
                                                                  WARRANT NO. 59

at the time of the record date for such dividend or on the effective date of
such split, subdivision, combination or reclassification, and/or the number and
kind of securities issuable on such date, shall be proportionately adjusted so
that the Holder of the Warrant thereafter exercised shall be entitled to receive
the aggregate number and kind of shares of Common Stock (or such other
securities other than Common Stock) of the Company, at the same aggregate
Warrant Price, that, if such Warrant had been exercised immediately prior to
such date, the Holder would have owned upon such exercise and been entitled to
receive by virtue of such dividend, distribution, split, subdivision,
combination or reclassification. Such adjustment shall be made successively
whenever any event listed above shall occur.

                  (b) In case the Company shall fix a record date for the making
of a distribution to all holders of Common Stock (including any such
distribution made in connection with a consolidation or merger in which the
Company is the surviving corporation) of cash, evidences of indebtedness or
assets, or subscription rights or warrants, the Warrant Price to be in effect
after such record date shall be determined by multiplying the Warrant Price in
effect immediately prior to such record date by a fraction, the numerator of
which shall be the Current Market Price per share of Common Stock on such record
date, less the amount of cash so to be distributed or the fair market value (as
determined in good faith by, and reflected in a formal resolution of, the board
of directors of the Company) of the portion of the assets or evidences of
indebtedness so to be distributed, or of such subscription rights or warrants,
applicable to one share of Common Stock, and the denominator of which shall be
the Current Market Price, as defined, per share of Common Stock. Such adjustment
shall be made successively whenever such a record date is fixed; and in the
event that such distribution is not so made, the Warrant Price shall again be
adjusted to be the Warrant Price which would then be in effect if such record
date had not been fixed.

                  (c) For purposes of this Warrant "Current Market Price" shall
mean: (i) if the principal trading market for such securities is a national
securities exchange, the Nasdaq Stock Market or the Over-the-Counter Bulletin
Board ("OTCBB") (or a similar system then in use), the last reported sales or
closing price on the principal market; or (ii) if (i) is not applicable, and if
bid and asked prices for shares of Common Stock are reported by the National
Quotation Bureau, Inc., the average of the high bid and low asked prices.
Notwithstanding the foregoing, if there is no last reported sales or closing
price or bid and asked prices, as the case may be, for the period in question,
then the "Current Market Price" shall be determined in good faith by, and
reflected in a formal resolution of, the board of directors of the Company.

                  (d) Notwithstanding any provision herein to the contrary, no
adjustment in the Warrant Price shall be required unless such adjustment would
require an increase or decrease of at least 1% in the Warrant Price; provided,
however, that any adjustments which by reason of this subsection (d) are not
required to be made shall be carried forward and taken into account in any
subsequent adjustment. All calculations under this Section 4 shall be made to
the nearest cent or the nearest one-hundredth of a share, as the case may be.

                  (e) In the event that at any time, as a result of an
adjustment made pursuant to Section 4(a) above, the Holder of any Warrant
thereafter exercised shall become entitled to receive any shares of capital
stock of the Company other than shares of Common Stock, thereafter the number of

                                       4
<PAGE>
                                                                  WARRANT NO. 59

such other shares so receivable upon exercise of any Warrant shall be subject to
adjustment from time to time in a manner and on terms as nearly equivalent as
practicable to the provisions with respect to the shares of Common Stock
contained in this Section 4, and the other provisions of this Warrant shall
apply on like terms to any such other shares.

                  (f) If the Company merges or consolidates into or with another
corporation or entity, or if another corporation or entity merges into or with
the Company (excluding such a merger in which the Company is the surviving or
continuing corporation and which does not result in any reclassification,
conversion, exchange, or cancellation of the outstanding shares of Common
Stock), or if all or substantially all of the assets or business of the Company
are sold or transferred to another corporation, entity, or person, then, as a
condition to such consolidation, merger, or sale (any "Transaction"), lawful and
adequate provision shall be made whereby the Holder shall have the right from
and after the Transaction to receive, upon exercise of this Warrant and upon the
terms and conditions specified herein and in lieu of the shares of the Common
Stock that would have been issuable if this Warrant had been exercised
immediately before the Transaction, such shares of stock, securities, or assets
as the Holder would have owned immediately after the Transaction if the Holder
had exercised this Warrant immediately before the effective date of the
Transaction.

                  (g) In case any event shall occur as to which the other
provisions of this Section 4 are not strictly applicable but the failure to make
any adjustment would not fairly protect the purchase rights represented by this
Warrant in accordance with the essential intent and principles hereof, then, in
each such case, the Company shall effect such adjustment, on a basis consistent
with the essential intent and principles established in this Section 4, as may
be necessary to preserve, without dilution, the purchase rights represented by
this Warrant.

         5. REGISTRATION RIGHTS. The Holder shall be entitled to the benefits as
provided in the Registration Rights Agreement, which is attached hereto as
Exhibit C.

         6. RESERVATION OF SHARES. The Company agrees at all times to reserve
and hold available out of its authorized but unissued shares of Common Stock the
number of shares of Common Stock issuable upon the full exercise of this
Warrant. The Company further covenants and agrees that all shares of Common
Stock that may be delivered upon the exercise of this Warrant will, upon
delivery, be fully paid and nonassessable and free from all taxes, liens and
charges with respect to the purchase thereof hereunder.

         7. NOTICES TO HOLDER. Upon any adjustment of the Warrant Price (or
number of shares of Common Stock purchasable upon the exercise of this Warrant)
pursuant to Section 4, the Company shall promptly thereafter cause to be given
to the Holder written notice of such adjustment. Such notice shall include the
Warrant Price (and/or the number of shares of Common Stock purchasable upon the
exercise of this Warrant) after such adjustment, and shall set forth in
reasonable detail the Company's method of calculation and the facts upon which
such calculations were based. Where appropriate, such notice shall be given in
advance and included as a part of any notice required to be given under the
other provisions of this Section 7.

                                       5
<PAGE>
                                                                  WARRANT NO. 59

         In the event of (a) any fixing by the Company of a record date with
respect to the holders of any class of securities of the Company for the purpose
of determining which of such holders are entitled to dividends or other
distributions, or any rights to subscribe for, purchase or otherwise acquire any
shares of capital stock of any class or any other securities or property, or to
receive any other right, (b) any capital reorganization of the Company, or
reclassification or recapitalization of the capital stock of the Company or any
transfer of all or substantially all of the assets or business of the Company
to, or consolidation or merger of the Company with or into, any other entity or
person, or (c) any voluntary or involuntary dissolution or winding up of the
Company, then and in each such event the Company will give the Holder a written
notice specifying, as the case may be (i) the record date for the purpose of
such dividend, distribution, or right, and stating the amount and character of
such dividend, distribution, or right; or (ii) the date on which any such
reorganization, reclassification, recapitalization, transfer, consolidation,
merger, conveyance, dissolution, liquidation, or winding up is to take place and
the time, if any is to be fixed, as of which the holders of record of Common
Stock (or such capital stock or securities receivable upon the exercise of this
Warrant) shall be entitled to exchange their shares of Common Stock (or such
other stock securities) for securities or other property deliverable upon such
event. Any such notice shall be given at least 10 days prior to the earliest
date therein specified.

         8. NO RIGHTS AS A STOCKHOLDER. This Warrant does not entitle the Holder
to any voting rights or other rights as a stockholder of the Company, nor to any
other rights whatsoever except the rights herein set forth.

         The Company shall comply with the reporting requirements of Sections 13
and 15(d) of the Securities Exchange Act of 1934 (the "Exchange Act") for so
long as and to the extent that such requirements apply to the Company.

         The Company shall not, by amendment of its Certificate of Incorporation
or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issuance or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant. Without limiting the generality of the foregoing, the Company (a) will
at all times reserve and keep available, solely for issuance and delivery upon
exercise of this Warrant, shares of Common Stock issuable from time to time upon
exercise of this Warrant, (b) will not increase the par value of any shares of
Common Stock receivable upon exercise of this Warrant above the amount payable
therefor upon such exercise, and (c) will take all such actions as may be
necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable stock.

         9. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
inure to the benefit of the Company, the Holder and their respective successors
and permitted assigns.

         10. NOTICES. The Company agrees to maintain a ledger of the ownership
of this Warrant (the "Ledger"). Any notice hereunder shall be given by Federal
Express or other overnight delivery service, or registered or certified mail if
to the Company, at its principal executive office and, if to the Holder, to its
address shown in the Ledger of the Company; provided, however, that either the

                                       6
<PAGE>
                                                                  WARRANT NO. 59

Company or the Holder may at any time on three days written notice to the other
designate or substitute another address where notice is to be given. Notice
shall be deemed given and received after a Federal Express or other overnight
delivery service is delivered to the carrier or a certified or registered
letter, properly addressed with postage prepaid, is deposited in the U.S. mail.

         11. SEVERABILITY. Every provision of this Warrant is intended to be
severable. If any term or provision hereof is illegal or invalid for any reason
whatsoever, such illegality or invalidity shall not affect the remainder of this
Warrant.

         12. GOVERNING LAW. This Warrant shall be governed by and construed in
accordance with the laws of the State of Delaware without giving effect to the
principles of choice of laws thereof.

         13. ATTORNEYS' FEES. In any action or proceeding brought to enforce any
provision of this Warrant, the prevailing party shall be entitled to recover
reasonable attorneys' fees in addition to its costs and expenses and any other
available remedies.

         14. ENTIRE AGREEMENT. This Warrant (including the Exhibits attached
hereto) constitutes the entire understanding between the Company and the Holder
with respect to the subject matter hereof, and supersedes all prior
negotiations, discussions, agreements and understandings relating to such
subject matter.

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its
duly authorized officer as of the date first set forth above.

                                       CyGene Laboratories, Inc.

                                       By:
                                          -----------------------
                                          Martin Munzer
                                          Chief Executive Officer

                                       7
<PAGE>
                                                                  WARRANT NO. 59

                                    Exhibit A

                                SUBSCRIPTION FORM

(To be Executed by the Holder to Exercise the Rights To Purchase Common Stock
Evidenced by the Within Warrant)

         The undersigned hereby irrevocably subscribes for _______ shares of the
Common Stock (the "Stock") of CyGene Laboratories, Inc. (the "Company") pursuant
to and in accordance with the terms and conditions of the attached Warrant (the
"Warrant"), and hereby makes payment of $_______ therefor by [tendering cash,
wire transferring or delivering a certified check or bank cashier's check,
payable to the order of the Company] [surrendering _______ shares of Common
Stock received upon exercise of the Warrant, which shares have a current market
price equal to such payment as required in Section 2 of the Warrant]. The
undersigned requests that a certificate for the Stock be issued in the name of
the undersigned and be delivered to the undersigned at the address stated below.
If the Stock is not all of the shares purchasable pursuant to the Warrant, the
undersigned requests that a new Warrant of like tenor for the balance of the
remaining shares purchasable thereunder be delivered to the undersigned at the
address stated below.

         In connection with the issuance of the Stock, I hereby represent to the
Company that I am acquiring the Stock for my own account for investment and not
with a view to, or for resale in connection with, a distribution of the shares
within the meaning of the Securities Act of 1933, as amended (the "Securities
Act").

         I understand that if at this time the Stock has not been registered
under the Securities Act, I must hold such Stock indefinitely unless the Stock
is subsequently registered and qualified under the Securities Act or is exempt
from such registration and qualification. I shall make no transfer or
disposition of the Stock unless (a) such transfer or disposition can be made
without registration under the Securities Act by reason of a specific exemption
from such registration and such qualification, or (b) a registration statement
has been filed pursuant to the Securities Act and has been declared effective
with respect to such disposition. I agree that each certificate representing the
Stock delivered to me shall bear substantially the same as set forth on the
front page of the Warrant.

         I further agree that the Company may place stop transfer orders with
its transfer agent same effect as the above legend. The legend and stop transfer
notice referred to above shall be removed only upon my furnishing to the Company
of an opinion of counsel (reasonably satisfactory to the Company) to the effect
that such legend may be removed.

Date:_______________________________      Signed: ______________________________
                                          Print Name:___________________________
                                          Address:______________________________

                                      A-1
<PAGE>
                                                                  WARRANT NO. 59

                                    Exhibit B

                                   ASSIGNMENT

(To be Executed by the Holder to Effect Transfer of the Attached Warrant)

For Value Received __________________________ hereby sells, assigns and
transfers to _________________________ the Warrant attached hereto and the
rights represented thereby to purchase _________ shares of Common Stock in
accordance with the terms and conditions hereof, and does hereby irrevocably
constitute and appoint ___________________________ as attorney to transfer such
Warrant on the books of the Company with full power of substitution.

Dated:________________________      Signed: _____________________________

Please print or typewrite                   Please insert Social Security
name and address of                         or other Tax Identification
assignee:                                   Number of Assignee:

                                      B-1
<PAGE>
                                                                  WARRANT NO. 59

                                    Exhibit C

                     EXECUTED REGISTRATION RIGHTS AGREEMENT

                                (To be attached.)

                                      C-1EXHIBIT 10.6

                              EMPLOYMENT AGREEMENT

This EMPLOYMENT AGREEMENT (the "Agreement") entered into as of this 20th day of
January, 2006, is by and between CyGene Laboratories, Inc., a Delaware
corporation (the "Company") and Peter J. Laurence (the "Executive").

         WHEREAS, the Company in its business has created, developed, and
acquired certain patented technology and trade secrets, including, but not
limited to, proprietary processes, sales methods and techniques, business and
technical information, including, but not limited to, designs, systems, business
and operational methods, pricing methods and rates, discounts, other processes,
procedures, formulas, hardware, and software, and improvements and modifications
thereof, whether patented, copyrighted, or protected as a trade secret, or
otherwise, that is of any value whatsoever to the Company, as well as certain
information relating to the Company's research and development, products and
services, information concerning proposed new products and services, marketing
and feasibility studies, proposed or existing marketing techniques or plans,
other Confidential Information, as defined below, and information about the
Company's employees, independent contractors, officers, and directors, which
necessarily will be communicated to, or ascertained by, the Executive by reason
of the Executive's employment by the Company; and

         WHEREAS, the Company has strong and legitimate business interests in
preserving and protecting its investment in the Executive, the Company's trade
secrets, and the Confidential Information, and the Company's substantial,
significant, or key relationships with its customers, suppliers, and vendors,
actual and prospective; and

         WHEREAS, the Company desires to preserve and protect its legitimate
business interests by restricting certain competitive activities of the
Executive during the term of his employment and following the termination of
employment for a reasonable time; and

         WHEREAS, the Company desires to employ the Executive and to ensure the
continued availability to the Company of the Executive's services, and the
Executive is willing to accept such employment and render such services, all
upon and subject to the terms and conditions contained in this Agreement.

         NOW, THEREFORE, in consideration of the premises and the mutual
covenants set forth in this Agreement, and intending to be legally bound, the
Company and the Executive agree that the above recitals are true and correct,
and further agree as follows:

         1.       REPRESENTATIONS AND WARRANTIES. The Executive hereby
represents and warrants to the Company that (i) there are no restrictions,
agreements, or understandings, to which Executive is party to, or otherwise
subject to, which does, or would, prevent or make unlawful, the Executive's
execution of this Agreement or the Executive's employment pursuant to this
Agreement, or which is or would be inconsistent, or in conflict with, this
Agreement or the Executive's employment pursuant to this Agreement, or would
prevent, limit, or impair, in any way, the performance by the Executive of his
obligations pursuant to this Agreement; and (ii) the Executive is not a party
to, or otherwise subject to, any nonsolicitation, noncompetition,
confidentiality, or nonuse/nondisclosure, restrictions, agreements, or
understandings, which does or could affect his employment with the Company; and
(iii) has not brought, and will not bring or use, any trade secrets,
confidential, or proprietary information, documents, or other intellectual,
intangible, or personal property, of a prior employer; and (iv) has not
previously been convicted of any felony; and (v) has not been previously
convicted or charged with any misdemeanor involving theft, fraud, embezzlement,
or perjury.

                                       1
<PAGE>

         2.       TERM OF EMPLOYMENT.

                  (a) Term. The Company hereby employs the Executive, and the
Executive hereby accepts employment with the Company for a period commencing on
the date of this Agreement and ending and/or renewing in accordance with the
terms of Section 6.

                  (b) Continuing Effect. Notwithstanding any termination of
employment, at the end of the term or otherwise, the provisions of Sections 7
and 8 shall remain in full force and effect and shall be binding upon the legal
representatives, successors and assigns of the Executive.

         3.       DUTIES.

                  (a) General Duties. The Executive shall serve as the Vice
President of Business Development of the Company, with duties and
responsibilities that are customary for such position. The Executive shall
report directly to the Company's Chief Executive Officer or as otherwise
directed by the board of directors of the Company. The Executive shall use his
best efforts to perform his duties and discharge his responsibilities pursuant
to this Agreement competently, carefully and faithfully.

                  (b) Devotion of Time. The Executive shall devote the majority
of his time, attention, and energy, during normal business hours (exclusive of
periods of sickness and disability and of such normal holiday and vacation
periods as established by the Company from time to time) to the affairs of the
Company. The Executive shall not enter the employ of, or serve as a consultant,
or adviser to, or in any way perform any services, with or without compensation
to, any other person, business, or organization with the exception of Laurence
Enterprises.

                  (c) Adherence to Inside Information Policies. The Executive
acknowledges that the Company is publicly-held and, as a result, has implemented
inside information policies designed to preclude its employees from violating
securities laws by trading on material, non-public information, or passing such
information on to others in breach of any duty owed to the Company, or any third
party. The Executive shall promptly execute any and all agreements distributed
by the Company to its employees requiring such employees to abide by its inside
information policies.

         4.       COMPENSATION AND EXPENSES.

                  (a) Salary. In consideration for the services of the Executive
rendered pursuant to this Agreement, during the Term of this Agreement,
Executive shall earn a base salary at the rate of $100,000 per year, which shall
be accrued on a quarterly basis and shall be paid, net of payroll taxes, once
the Company has either received $1 million in debt or equity financing or once
the Company has achieved quarterly annualized revenues of $1 million based on
the most recent quarterly report. In addition, the Executive shall be entitled
to a bonus of 2% of gross profit achieved by the Company through the sales of
its products [gross profit shall be defined to be total revenue from sales minus
the aggregate cost of product packaging and processing]. Such bonus shall be
calculated at the end of each fiscal quarter and be paid in cash. In the event
that the Company closes one or more financing transactions whereby the Company
raises capital through the issuance or sale of securities (or a combination
thereof) or through a loan from a bank, financial institution, or other lender,
or a syndicate thereof, which in the aggregate provides funds to the Company, of
at least $2,500,000, the Executive's annual salary shall be increased to
$240,000 per year effective for the balance of the Term of this Agreement. Said
increase in base salary shall also take effect in the event that the Company
derives annualized gross revenues in any quarter in excess of $1,500,000 and, in
both cases, shall begin with the first quarter following the quarter where the

                                       2
<PAGE>

qualifying revenues were booked, or in which the loans or other funding were
received.

                  (b) Expenses. In addition to any compensation earned pursuant
to Section 4(a), the Company shall reimburse or advance funds to the Executive
for all reasonable travel, entertainment, and miscellaneous expenses that are
documented by the Executive and incurred in connection with the performance of
his duties pursuant to this Agreement, in conformance with the Company's
policies as existing from time to time.

                  (c) Performance Bonuses.

                      (i) If the Company's  gross revenues exceed  $2,500,000
for fiscal year 2006, $5,000,000 for fiscal year 2007, and/or $10,000,000 for
fiscal year 2008 the Company shall issue to the Executive 200,000 5-year
warrants to purchase shares of common stock in the Company as a bonus for each
such year. The exercise price shall be 100% of the average closing price of the
Company's common stock for the last calendar month of the fiscal year for which
the warrants were earned.

                      (ii) Market Value Bonus: The executive shall be entitled
to a bonus based on increases in the Company's Market Capitalization (as defined
below). In the event that the Company Market Capitalization as of the end of any
fiscal quarter during the Term of this Agreement exceeds $50,000,000, you shall
accrue a one-time bonus of $100,000. Thereafter, you shall accrue an additional
bonus at the end of each fiscal quarter in an amount equal to 0.5% of the
amount, if any, by which the Company's Market Capitalization as of the end of
such quarter was in excess of the greater of (i) $50,000,000, or (ii) the amount
of the Company's Market Capitalization as of the most recent quarter for which a
bonus has been accrued to the Executive under this Section 4(c)(ii). All such
bonuses shall be paid in cash within 10 days after the filing of the company's
quarterly reports. As used herein, "Company's Market Capitalization" means, as
of the last day of any fiscal quarter, an amount equal to the average closing
price of the Company's common stock for the twenty (20) trading day period
ending on such day, multiplied by the total number of shares of the Company's
common stock issued and outstanding as of such day.

                      (iii) The warrants issued under this Section 4(c) shall be
irrevocable.

                  (d) Discretionary Bonus. Discretionary bonuses may be awarded
to the Executive by the Company's board of directors based on subjective
criteria (unrelated to actual operating results) evaluating the Executive's
efforts in connection with the Company's achievements, which may result in
future expansion and revenue.

                  (e) Initial Warrants. As further consideration for Executive's
covenants hereunder, the Company shall issue to Executive, upon execution of
this Agreement, 5-year warrants for the purchase of 650,000 shares of the common
stock of the Company, at an exercise price $0.50 per share.

                  (f) Terms and Exercise of Warrants. All warrants to be issued
to Executive under this Agreement shall be evidenced by five-year warrant
agreements in the form of Exhibit A attached to this Agreement. Warrants issued
under this Agreement shall have piggyback registration rights.

         5.       BENEFITS. Except for accrued vacation under Section 5(a), and
the benefits described under Section 5(c), no other benefits are available
during the first 90 days of this Agreement.

                                       3
<PAGE>

                  (a) Vacation. During the term of employment, the Executive
shall be entitled to three weeks of vacation per year, in each instance without
loss of compensation or other benefits to which the Executive is entitled under
this Agreement, to be taken at such times as the Executive may request and the
affairs of the Company may permit.

                  (b) Employee Benefit Programs. The Executive is entitled to
participate in any insurance, pension, 401(k), or other employee benefit plan
that is maintained by the Company for its employees, including programs of life
and medical insurance and reimbursement of membership fees in professional
organizations.

                  (c) Insurance. The Company shall pay the premiums on the
Company's medical insurance policy covering the Executive.

         6.       TERMINATION.

                  (a) General Provisions. Upon effectiveness of such
termination, the Executive shall have no right to compensation or reimbursement
under Section 4 or to participate in any employee benefit programs under Section
5, except as may be expressly provided for by law for any period subsequent to
the effective date of termination. On or before the termination of the
Executive's employment or prior to receiving any final compensation or expenses
due him, the Executive shall (a) return to the Company's principal executive
offices, (b) participate in an exit interview, and (c) execute a Certificate of
Conclusion of Employment, certifying that he has complied with all of his
obligations herein and acknowledging his continuing obligations pursuant to this
Agreement. The Executive's failure to comply with the requirements of Section 6
of this Agreement shall constitute a material breach of this Agreement. The base
term of Executive's employment with the Company will be three (3) years. After
each year of employment, the Term of this Agreement and of Executive's
employment with the Company will automatically be extended an additional year,
such that the balance of the Term will never be less than two (2) years. If the
Executive is terminated by the Company other than for Cause (defined below), or
he resigns for Good Reason, as defined in 4(a), he shall continue to receive his
bonus compensation for the remaining Term of this Agreement. If such termination
occurs within the first three (3) years of this Agreement, Executive will
receive his base salary in addition to his bonus compensation for the remaining
Term of this Agreement. Provided Executive has been employed with Company for at
least eighteen (18) months, then upon Executive's death, permanent disability or
mental incapacity, any monies owed to Executive under this Section 6(a) shall be
paid to Executive's estate upon his death or his guardian upon his permanent
disability or mental incapacity.

                  (b) Termination for Cause. The Company may terminate the
Executive's employment pursuant to the terms of this Agreement at any time for
Cause by giving express written notice of termination. Upon any such termination
for Cause or in the event of his resignation or abdication form his position
with the Company, the Executive shall have no right to compensation or
reimbursement under Section 4, or to participate in any employee benefit
programs under Section 5, except as may be expressly provided by law, for any
period subsequent to the effective date of termination. For purposes of this
Section 6(b), for "Cause" shall mean the Executive: (i) is convicted of any
felony; (ii) is charged with any felony relating to the business or affairs of
the Company or any affiliate of the Company, or is charged with any felony or
misdemeanor relating to any theft, fraud, misappropriation, embezzlement, or
perjury; (iii) is convicted of any misdemeanor directly involving the

                                       4
<PAGE>

Executive's employment or which directly affects the business of the Company;
(iv) is found after an internal investigation by the Company to have engaged in
any sexual misconduct or sexual harassment which is related to the Executive's
employment or the business of the Company or places, rightly or wrongly, the
Company at risk for litigation in connection therewith; (v) misappropriates any
Company funds or otherwise defrauds the Company; (vi) is convicted of the
illegal possession or illegal use of a controlled substance; (vii) engages in
chronic absenteeism, or alcohol or substance abuse; (viii) the Executive fails
or refuses to cooperate in any official investigation conducted by or on behalf
of the Company; (ix) the Executive materially breaches any provision of this
Agreement; or (x) the Executive on more than one occasion fails to comply with
the reasonable directives of the Company's Chief Executive Officer or its board
of directors after written notification.

                  (c) Good Reason. The Executive may terminate this Agreement
for "Good Reason." "Good Reason" shall mean, (i) a material breach by the
Company of its obligations under this Agreement; or (ii) the material alteration
or restriction of the Executive's authority and responsibility in a manner
inconsistent with his position, duties, responsibilities and status with the
Company.

                  You may terminate your employment for "Good Reason" on thirty
(30) days Notice of Termination to the Company in the event of a Change in
Control, as provided for in paragraph 2.6.

                  Notice of Termination for Change in Control must be given
within 3 months of the Change in Control. Failure to provide notice as provided
in this section 2.5 shall constitute a consent to such failure or change, and a
waiver of the right to terminate the agreement based on such action;

                  For purposes of this Agreement, a "Change in Control" shall
mean any of the following events:

                  (a) An acquisition (other than directly from the Company) of
any voting securities of the Company (the "Voting Securities") by any "Person"
(as the term person is used for purposes of Section 13(d) or 14(d) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act")), immediately
after which such Person has "Beneficial Ownership" (within the meaning of Rule
13d-3 promulgated under the Exchange Act) of thirty percent (30%) or more of the
combined voting power of the Company's then outstanding Voting Securities;
provided, however, in determining whether a Change in Control has occurred,
Voting Securities that are acquired in a "Non-Control Acquisition" (as
hereinafter defined) shall not constitute an acquisition that would cause a
Change in Control. A "Non-Control Acquisition" shall mean an acquisition by (i)
an employee benefit plan (or a trust forming a part thereof) maintained by (A)
the Company or (B) any corporation or other Person of which a majority of its
voting power or its voting equity securities or equity interest is owned,
directly or indirectly, by the Company (for purposes of this definition, a
"Subsidiary"), (ii) the Company or its Subsidiaries, or (iii) any Person in
connection with a "Non-Control Transaction," as hereinafter defined;

                  (b) The individuals who, constitute the Board of Directors
cease to constitute a majority of the members of the Company's Board of
Directors (the "Incumbent Board"); provided, however, that if the election, or
nomination for election by the Company's stockholders, of any new director was
approved by a vote of the Incumbent Board as provided in they bylaws of the
Corporation, such new director shall, for purposes of this Plan, be considered
as a member of the Incumbent Board; provided further, however, that no
individual shall be considered a member of the Incumbent Board if such
individual initially assumed office as a result of either an actual or
threatened "Election Contest" (as described in Rule 14a-11 promulgated under the
Exchange Act) or other actual or threatened solicitation of proxies or consents
by or on behalf of a Person other than the Board (a "Proxy Contest") including
by reason of any agreement intended to avoid or settle any Election Contest or
Proxy Contest; or

                  (c) Approval by stockholders of the Company of:

                                       5
<PAGE>

                      (i) A merger, consolidation or reorganization involving
                  the Company, unless such merger, consolidation or
                  reorganization is a "Non-Control Transaction." A "Non-Control
                  Transaction" shall mean a merger, consolidation or
                  reorganization of the Company where:

                          (A) the stockholders of the Company, immediately
                      before such merger, consolidation or reorganization, own
                      directly or indirectly immediately following such merger,
                      consolidation or reorganization, at least fifty percent
                      (50%) of the combined voting power of the outstanding
                      voting securities of the corporation resulting from such
                      merger or consolidation or reorganization (the "Surviving
                      Corporation")

                          (B) the individuals who were members of the Incumbent
                      Board immediately prior to the execution of the agreement
                      providing for such merger, consolidation or reorganization
                      constitute more than 50 percent of the members of the
                      board of directors of the Surviving Corporation, or a
                      corporation beneficially directly or indirectly owning a
                      majority of the Voting Securities of the Surviving
                      Corporation, and

                      (ii) A complete liquidation or dissolution of the Company;
                  or

                      (iii) An agreement for the sale or other disposition of
                  all or substantially all of the assets of the Company to any
                  Person (other than a transfer to a parent, a subsidiary or
                  other corporation which would constitute a Non-Control
                  Transaction under paragraph (i) above.

                  (d) Notwithstanding the foregoing, a Change in Control shall
not be deemed to occur solely because any Person (the "Subject Person") acquired
Beneficial Ownership of more than the permitted amount of the then outstanding
Voting Securities as a result of the acquisition of Voting Securities by the
Company which, by reducing the number of Voting Securities then outstanding,
increases the proportional number of shares Beneficially Owned by the Subject
Person, provided that if a Change in Control would occur (but for the operation
of this sentence) as a result of the acquisition of Voting Securities by the
Company, and after such share acquisition by the Company, the Subject Person
becomes the Beneficial Owner of any additional Voting Securities that increases
the percentage of the then outstanding Voting Securities Beneficially Owned by
the Subject Person, then a Change in Control shall occur.

                  (e) Performance. The Company may at its discretion terminate
this agreement with the Executive, if it has not achieved $1.5 million in gross
profit (as that term is defined herein) during the first year of this Agreement.

         7.       NON-COMPETITION AGREEMENT.

                  (a) Competition with the Company. Until termination of his
employment and for a period of 12 months commencing on the date of termination,
the Executive, or in association with or as a stockholder, owner, lender,
director, officer, consultant, employee, independent contractor, partner,
associate, joint venturer, member or otherwise of or through any person, firm,
corporation, partnership, association or other entity (any of the foregoing
defined as an "Affiliated Entity") shall not directly or indirectly act as an

                                       6
<PAGE>

executive for any person, firm, or entity, which competes with the Company or
its affiliates, within any metropolitan area in the United States or elsewhere
in which the Company or any of its subsidiaries, partners, affiliates (as
defined in the Securities Exchange Act of 1934, as amended), or joint venturers,
(collectively, the "Affiliates") is then engaged in the offer and sale of
competitive Products or Services (as defined below). Provided, however, the
foregoing provisions shall not prevent the Executive from accepting employment
or receiving remuneration with or from an enterprise engaged in two or more
lines of business, one of which is the same or similar to the Company's business
(the "Prohibited Business") if the Executive's employment is totally unrelated
to the Prohibited Business; provided, further, the foregoing shall not prohibit
Executive from owning up to 5% of the securities of any publicly-traded
enterprise provided the Executive is not an employee, director, officer,
independent contractor or consultant to such enterprise, nor is otherwise
reimbursed or remunerated for services rendered to such enterprise. In addition,
the Executive may not, directly or indirectly, including through any Affiliated
Entity, obtain employment with or perform services for any Customer of the
Company, during the period commencing on the date of termination and continuing
for 12 months thereafter.

                  (b) Solicitation of Customers. During the periods in which the
provisions of Section 7(a) shall be in effect, the Executive, shall not directly
or indirectly, including through any Affiliated Entity, (i) seek, or accept, any
Prohibited Business from any Customer on behalf of any enterprise or business
other than the Company, (ii) refer Prohibited Business from any Customer to any
enterprise or business other than the Company or receive commissions based on
sales or otherwise relating to the Prohibited Business from any Customer, or any
enterprise or business other than the Company. For purposes of this Agreement,
the term "Customer" means any person, firm, corporation, partnership,
association, or other entity, to which the Company sold or provided products
and/or services during the 24-month period prior to the time at which any
determination is required to be made as to whether any such person, firm,
corporation, partnership, association, or other entity is a Customer, or who or
which was approached by, or who or which has approached, an employee or
independent contractor of the Company for the purpose of soliciting business
from the Company or the third party, as the case may be.

                  (c) Solicitation of Employees and Certain Others. During the
periods in which the provisions of Section 7(a) shall be in effect, the
Executive, shall not, directly or indirectly, including through any Affiliated
Entity, solicit, hire, retain, entice, interfere with, or contact any employee,
independent contractor, officer, director, or representative, of the Company, or
any of its subsidiaries, for the purpose of (i) hiring them, having another
person or entity hire them, (ii) offering any employment, the procuring of
employment, or causing the Executive to alter, modify, or terminate, their
employment, or other relationship, as the case may be, with the Company, (iii)
providing any assistance regarding any employment offer, agreement,
relationship, or other assistance, in connection with procuring or attempting to
procure employment.

                  (d) References to the Company in this Section 7 shall include
the Company's Affiliates.

         8.       CONFIDENTIAL INFORMATION. The Executive shall not disclose or
use at any time, either during the Term or for a period of two years after the
Termination Date, any Confidential Information (defined below) of the Company,
whether patentable or not, which you learn as a result of your employment with
the Company, whether or not you developed such information. "CONFIDENTIAL
INFORMATION" shall include, without limitation: terms of contracts with
customers, including, contracts with suppliers, independent contractors or
employees; business plans and forecasts, non-public financial information and
investor identities; personnel information relating to the duties and
responsibilities of, and compensation and benefits provided to, any employee;
names, home address and phone numbers of employees; sales and marketing
strategies, plans and programs; product development information; specifications;
inventions, discoveries, improvements, trade secrets, secret processes,
technology, know-how, models, drawings, works of authorship or other creative
works, ideas, knowledge, data and any other information which the Company

                                       7
<PAGE>

regards as confidential. Confidential Information shall remain at all times the
property of the Company.

                  (a) For the purposes of this Agreement, "CONFIDENTIAL
INFORMATION" shall not include information that:

                      (i) is or has been made available to the public by any
                  means, through no fault of your own and without breach of this
                  Agreement; or

                      (ii) is already in your possession without restriction and
                  prior to any disclosure hereunder and can be so established by
                  you; or

                      (iii) is or has been lawfully disclosed to you by a third
                  party without an obligation of confidentiality upon you; or

                      (iv) is developed independently by you without benefit
                  from Confidential Information disclosed hereunder.

         You may use or disclose Confidential Information only:

         (a) as authorized and necessary in performing your duties and
responsibilities in accordance with this Agreement;

         (b) with the Company's prior written consent;

         (c) in a legal proceeding between you and the Company to establish the
rights of either party under this Agreement, provided that you stipulate to a
protective order to prevent any unnecessary use or disclosure; or

         (d) subject to a compulsory legal process that requires disclosure of
such information, provided that you have complied with the following procedures
to ensure that the Company has an adequate opportunity to protect its legal
interests in preventing disclosure:

             Upon receipt of a subpoena that could possibly require disclosure
             of Confidential Information, you provide a copy of the compulsory
             process and complete information regarding the circumstances under
             which you received it to the Company by hand delivery within 72
             hours. If the Company seeks to prevent disclosure in accordance
             with the applicable legal procedures, and provides you with notice
             before the appearance date specified in the subpoena that it has
             initiated such procedures, you will not make disclosures of any
             Confidential Information that is the subject of such procedures,
             until such objections are withdrawn or ruled on.

         You hereby acknowledge that any breach of this section 5 would cause
the Company irreparable harm.

             (d) References to the Company in this Section 8 shall include the
Company's Affiliates.

                                       8
<PAGE>

         9.       EQUITABLE RELIEF.

                  (a) The Company and the Executive recognize that the services
to be rendered under this Agreement by the Executive are special, unique and of
extraordinary character, and that in the event of the breach by the Executive of
the terms and conditions of this Agreement or if the Executive, shall cease to
be an employee of the Company for any reason and take any action in violation of
Section 7 and/or Section 8, the Company shall be entitled to, in addition to all
other legal, equitable, and other remedies, may institute and prosecute
proceedings in any court of competent jurisdiction referred to in Section 9(b)
below, to enjoin the Executive from breaching the provisions of Section 7 and/or
Section 8. In such action or proceeding, the Company shall not be required to
plead or prove irreparable harm or lack of an adequate remedy at law or post any
bond or security.

                  (b) In the event of any litigation or other proceeding
relating to, or in connection with, this Agreement, including, but not limited
to the equitable relief provided in Section 9(a) above, the Executive and the
Company irrevocably and unconditionally submit to the exclusive jurisdiction and
venue of Broward County, Florida, and agree to take any and all future action
necessary to submit to the jurisdiction and venue of such courts. The Executive
and the Company irrevocably waive any objection that they now have or hereafter
may have to the jurisdiction and the laying of venue of any suit, action or
proceeding brought in any such court, and further irrevocably waive any claim
that any such suit, action or proceeding brought in any such court has been
brought in an inconvenient forum. Final judgment against the Executive or the
Company in any such suit shall be conclusive and may be enforced in other
jurisdictions by suit on the judgment, a certified or true copy of which shall
be conclusive evidence of the fact and the amount of any liability of the
Executive or the Company therein described.

         10.      CONFLICTS OF INTEREST. While employed by the Company, the
Executive shall not, directly or indirectly, unless approved by prior express
written consent of the Chief Executive Officer and the Company's board of
directors:

                  (a) participate as an individual in any way in the benefits of
any transaction or in dealings with any of the Company's suppliers, clients, or
customers, including, but not limited to, having a financial interest in the
Company's suppliers, clients, or customers, or making loans to, or receiving
loans, from, the Company's suppliers, clients, or customers;

                  (b) realize a personal gain or advantage from a transaction in
which the Company has an interest or use information obtained in connection with
the Executive's employment with the Company for the Executive's personal
advantage or gain. The Company acknowledges and accepts that the Executive
currently receives, and may continue to receive, residual income from the
network marketing company Mannatech which may in the future be partially derived
from Mannatech's sale of CyGene competitors products; or

                  (c) serve as an officer, director, adviser, partner,
consultant, member, independent contractor, or manager, with, or to be employed
by, any person or entity which does business with the Company.

                  (d) As used in Section 10(a), (b) or (c), the Company also
includes its Affiliates.

         11.      INVENTIONS, IDEAS, PROCESSES, AND DESIGNS. All inventions,
ideas, processes, programs, software, algorithms, hardware, developments,
models, research, and designs, including, but not limited to all alterations,

                                       9
<PAGE>

modifications, and improvements thereon, (collectively, "Developments"), which
are (i) conceived, created, or made by the Executive during the course of his
employment with the Company (whether or not during regular business hours) and
for a period of six months subsequent to the termination or expiration of such
employment with the Company and (ii) which are related to the business of the
Company, shall be disclosed by the Executive, in reasonable detail and
specificity, in writing, promptly, but in no event later than 30 days of such
Development, to the Company, and shall be the sole and exclusive property of the
Company. The phrase "related to the business of the Company" shall mean to
include, but shall not be limited to, if the Development was (a) made in whole
or in part with any of the Company's equipment, supplies, facilities, assets,
personnel, funds, or Confidential Information, (b) results from work in whole or
in part performed by the Executive or any employee for the Company, or (c)
pertains to the current business, planned prospect work, or demonstrably
anticipated research or development work of the Company. The Executive shall
cooperate with the Company and the Company's attorneys in the preparation of any
and all patent, and copyright applications, and other methods of protection, for
such Developments and, upon request, shall promptly, but in no event later than
30 days of such Development, convey and assign any and all such Developments to
the Company upon the Company's request. The decision to file for patent or
copyright protection or to maintain such Development as a trade secret, and to
make other applications, or to otherwise protect such property, shall be in the
sole discretion of the Company, and the Executive shall be bound by such
decisions. The Executive shall provide as a schedule to this Agreement, a
complete list of all Developments, including brief descriptions, which he made
or conceived prior to his employment with the Company and which therefore are
excluded from the scope of this Agreement.

         12.      INDEBTEDNESS. If, during the course of the Executive's
employment under this Agreement, the Executive becomes indebted to the Company
for any reason, the Company may, if it so elects, set off payments due the
Executive by the Company, by the amounts due to the Company from the Executive,
and collect any remaining balance from the Executive.

         13.      EXEMPT STATUS OF TRANSACTION. Company warrants and represents
that Executive is not an officer, principal stockholder or director of the
Company and that the transactions contemplated by this Agreement are exempt from
the operation of Section 16(c) of the Securities Exchange Act of 1934 as amended
from time to time. Company warrants and represents that Executive will not be
the beneficial owner of more than ten percent (10%) of the equity security of
the Company under the terms of this Agreement and therefore securities
registration is not required under the transactions referenced herein.

         14.      ASSIGNABILITY. The rights and obligations of the Company under
this Agreement shall inure to the benefit of and be binding upon the successors
and assigns of the Company, provided that such successor or assignee shall
acquire all or substantially all of the assets, business, and/or securities of
the Company by means of split-off, spin-off, reorganization, liquidation,
dissolution, merger, consolidation, amalgamation, combination, transfer, or
otherwise. Neither the Executive's right or obligations hereunder may be
assigned, hypothecated, or alienated, and any attempt to do so by the Executive
will be void.

         15.      SEVERABILITY.

                  (a) The Executive expressly agrees that the character,
duration and geographical scope of the non-competition provisions set forth in
this Agreement are reasonable in light of the circumstances as they exist on the
date hereof. Should a decision, however, be made at a later date by a court of
competent jurisdiction that the character, duration, or geographical scope of
such provisions is unreasonable, then it is the intention and the agreement of

                                       10
<PAGE>

the Executive and the Company that this Agreement shall be construed by the
court in such a manner as to impose only those restrictions on the Executive's
conduct that are reasonable in the light of the circumstances and as are
necessary to assure to the Company the benefits and protections contained in
this Agreement. If, in any litigation or proceeding, a court of competent
jurisdiction shall refuse to enforce all of the separate covenants deemed
included herein (or the scope thereof) because taken together they are more
extensive than necessary to assure to the Company the intended benefits and
protections contained herein, it is expressly understood and agreed by the
parties hereto that the provisions of this Agreement that, if further limited or
eliminated, would permit the remaining provisions and separate covenants (or the
scope thereof) to be enforced shall be deemed further limited or eliminated, for
the purposes of such proceeding, from this Agreement.

                  (b) If any provision of this Agreement otherwise is deemed to
be invalid or unenforceable or is prohibited by the laws of the state or
jurisdiction where it is to be performed, this Agreement shall be considered
severable as to such provision and such provision shall be inoperative in such
state or jurisdiction and shall not be part of the consideration moving from
either of the parties to the other. The remaining provisions of this Agreement
shall be valid and binding and of like effect as though such provision was not
included.

         16.      NOTICES AND ADDRESSES. All notices, offers, acceptance and any
other acts under this Agreement (except payment) shall be in writing, and shall
be sufficiently given if delivered to the addressees in person, by Federal
Express or similar receipted delivery, or by facsimile delivery in which event a
copy shall immediately be sent by Federal Express or similar receipted delivery.

         To the Company:            CyGene Laboratories, Inc.
                                    7786 Wiles Road
                                    Coral Springs, FL 33067
                                    Attention: Mr. Martin Munzer,
                                               Chief Executive Officer

         With a Copy to:            Michael S. Blass
                                    Arent Fox PLLC
                                    1675 Broadway, 34th Floor
                                    New York, NY 10019

         To the Executive:          Peter J. Laurence
                                    8419 E. Cortez Street
                                    Scottsdale, AZ 85260

         With a Copy to:            Darrell E. Davis
                                    NORLING, KOLSRUD, SIFFERMAN & DAVIS, P.L.C.
                                    16427 N. Scottsdale Road, Suite 210
                                    Scottsdale, Arizona  85254

or to such other address as either of them, by notice to the other may designate
from time to time. The transmission confirmation receipt from the sender's
facsimile machine shall be evidence of successful facsimile delivery. Time shall
be counted to, or from, as the case may be, the delivery in person or by
mailing.

                                       11
<PAGE>

         17.      COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together shall constitute one and the same instrument. The execution of this
Agreement may be by actual or facsimile signature.

         18.      ATTORNEYS' FEES. In the event that there is any controversy or
claim arising out of or relating to this Agreement, or to the interpretation,
breach or enforcement thereof, and any action or proceeding is commenced to
enforce the provisions of this Agreement, the prevailing party shall be entitled
to a reasonable attorneys' fees, costs and expenses.

         19.      GOVERNING LAW. This Agreement and any dispute, disagreement,
or issue of construction or interpretation arising hereunder whether relating to
its execution, its validity, the obligations provided therein or performance
shall be governed and interpreted according to the internal laws of the State of
Florida without regard to choice of law considerations.

         20.      ENTIRE AGREEMENT. This Agreement constitutes the entire
agreement between the parties and supersedes all prior oral and written
agreements between the parties hereto with respect to the subject matter hereof.
Neither this Agreement nor any provision hereof may be changed, waived,
discharged or terminated, except by a statement in a prior express writing
signed by the party or parties against which enforcement or the change, waiver
discharge or termination is sought.

         21.      ADDITIONAL DOCUMENTS. The parties hereto shall execute such
additional instruments as may be reasonably required by their counsel in order
to carry out the purpose and intent of this Agreement and to fulfill the
obligations of the parties hereunder.

         22.      SECTION AND PARAGRAPH HEADINGS. The section and paragraph
headings in this Agreement are for reference purposes only and shall not affect
the meaning or interpretation of this Agreement.

IN WITNESS WHEREOF, the Company and the Executive have entered into this
Agreement as of the date and year first above written.

                                            CYGENE LABORATORIES, INC.

______________________________              By:__________________________
                                               Martin Munzer
                                               Chief Executive Officer

                                            EXECUTIVE:

________________________________            By:________________________________
                                               Peter J. Laurence

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00104-of-00352.parquet"}]]